Verastem (NASDAQ:VSTM – Get Free Report) had its price objective decreased by stock analysts at HC Wainwright from $17.50 to $7.00 in a report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price target points to a potential upside of 199.15% from the stock’s current price.
A number of other brokerages have also recently weighed in on VSTM. Alliance Global Partners decreased their price target on shares of Verastem from $34.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday, May 29th. B. Riley decreased their target price on Verastem from $21.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Truist Financial lowered their target price on Verastem from $34.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, July 8th. StockNews.com lowered Verastem from a “hold” rating to a “sell” rating in a research report on Thursday, August 1st. Finally, Royal Bank of Canada decreased their price target on Verastem from $16.00 to $13.00 and set an “outperform” rating for the company in a report on Friday. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, Verastem presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.29.
Get Our Latest Stock Report on VSTM
Verastem Trading Down 0.4 %
Verastem (NASDAQ:VSTM – Get Free Report) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by ($0.10). On average, sell-side analysts anticipate that Verastem will post -4 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Verastem
Hedge funds have recently bought and sold shares of the business. International Assets Investment Management LLC raised its position in shares of Verastem by 114,375.0% in the 4th quarter. International Assets Investment Management LLC now owns 9,158 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 9,150 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Verastem by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,160,931 shares of the biopharmaceutical company’s stock worth $13,699,000 after buying an additional 10,678 shares during the last quarter. Cannon Global Investment Management LLC acquired a new stake in Verastem in the first quarter valued at $131,000. Acadian Asset Management LLC bought a new position in Verastem during the 2nd quarter valued at $82,000. Finally, Rhumbline Advisers grew its holdings in Verastem by 4,172.0% during the 2nd quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 28,119 shares in the last quarter. Institutional investors and hedge funds own 88.37% of the company’s stock.
About Verastem
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Read More
- Five stocks we like better than Verastem
- Investing In Preferred Stock vs. Common Stock
- How to Invest in Silver: A Beginner’s Guide
- How to Use Stock Screeners to Find Stocks
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- What is the Australian Securities Exchange (ASX)
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.